(Q40275058)

19 September 2017

title

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer (English)

1 reference

19 September 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

H G Strauss

1

1 reference

19 September 2017

A Henze

2

1 reference

19 September 2017

A Teichmann

3

1 reference

19 September 2017

I Karbe

4

1 reference

19 September 2017

A Baumgart

5

1 reference

19 September 2017

C Thomssen

6

1 reference

19 September 2017

H Koelbl

7

1 reference

19 September 2017

language of work or name

English

0 references

publication date

27 October 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

104

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

612-616

1 reference

The role of surgery in recurrent ovarian cancer

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.023

10.1016/J.YGYNO.2006.09.023

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference